Gastric Cancer
Conditions
Interventions
Conventional control group:Participants randomized to the conventional control group will be managed according to the current routine screening and follow-up surveillance strategy:
(1) Participants wi
(2) Participants with low-grade intraepithelial neoplasia will undergo endoscopic screening and follow-up once every year.
Risk-stratified intervention group:A risk assessment model will be used to stratify patients according to their risk levels. All study participants will receive health education on healthy lifestyle b
Sponsors
Cancer Hospital,Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 40–75 years, regardless of sex; 2. Individuals who have a definitive diagnosis of precancerous lesions with intestinal metaplasia or low-grade intraepithelial neoplasia, as confirmed by gastroscopy and histopathological examination of the gastric mucosa; 3. Individuals who agree to comply with the stratified intervention management protocol; 4. Participants who are fully informed and voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Individuals with endoscopic and histopathological findings before enrollment indicating high-grade intraepithelial neoplasia, gastric cancer, or esophageal lesions of high-grade or above; 2.Individuals with severe cardiovascular, cerebrovascular, respiratory, hepatic, renal, or hematopoietic system diseases, such as severe heart failure, severe asthma, or aortic aneurysm; 3.Individuals in poor physical condition who are unable to tolerate gastroscopy; 4.Individuals in the acute phase of corrosive inflammation of the upper gastrointestinal tract or with suspected perforation; 5.Pregnant women; 6.Individuals with a history of iodine allergy; 7.Individuals with severe mental illness, intellectual impairment, or language disorders who are unable to accurately describe symptoms or cooperate with the study procedures; 8.Individuals currently participating in other drug clinical trials, or those whose study adherence may be affected by severe organic diseases; 9.Individuals who have previously undergone gastric surgery, endoscopic submucosal dissection (ESD), or endoscopic mucosal resection (EMR); 10. Individuals with clinical, endoscopic, or serological evidence suggestive of autoimmune gastritis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cumulative incidence of gastric cancer; | — |
Secondary
| Measure | Time frame |
|---|---|
| Lesion progressive rate;The proportion of early gastric cancer cases among detected gastric cancer cases ;Lesion regression rate;Safety;compliance /feasibility; | — |
Countries
China
Contacts
Public ContactLi Li
Cancer Hospital,Chinese Academy of Medical Sciences
Outcome results
None listed